Lung function trajectories in a cohort of patients with moderate‐to‐severe asthma on mepolizumab, omalizumab, or dupilumab
Allergy · 2024
DOI: 10.1111/all.16002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, 2024. Verfasst von Tanawin Nopsopon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Omalizumab, Anti-Asthmatic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIMHD NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Background
Lung function is an independent predictor of mortality. We evaluated the lung function trajectories of a cohort of patients with asthma receiving biologic therapy.
Methods
We identified 229 monoclonal antibody‐naïve adult patients with moderate‐to‐severe asthma who initiated omalizumab, mepolizumab, or dupilumab between 2010 and 2022 in a large healthcare system in Boston, MA. Generalized additive mixed models were used to estimate the lung function trajectories during the 156 weeks following biologic initiation. Response was defined as an improvement in FEV 1 or a decrease of ≤0.5% per year. The Kaplan–Meier estimator was used to assess time to no additional improvement in FEV 1 in responders. All models were adjusted for age, sex, body mass index, smoking status, baseline exacerbation rate, and baseline blood eosinophil count.
Results
Eighty‐eight patients initiated mepolizumab, 76 omalizumab, and 65 dupilumab. Baseline eosinophil count was highest in the mepolizumab group (405 cells/mcL) and lowest for omalizumab (250 cells/mcL). Both FEV 1 and FVC improved in the mepolizumab group (FEV 1 + 20 mL/year; FVC +43 mL/year). For omalizumab, there was an initial improvement in the first year followed by decline with an overall FEV 1 loss of −44 mL/year and FVC −32 mL/year. For dupilumab, both FEV 1 (+61 mL/year) and FVC (+74 mL/year) improved over time. Fifty percent of the mepolizumab group, 58% omalizumab, and 72% of dupilumab were responders. The median time to no additional FEV 1 improvement in responders was 24 weeks for omalizumab, 48 weeks for mepolizumab, and 57 weeks for dupilumab.
Conclusion
In this clinical cohort, mepolizumab, omalizumab, and dupilumab had beneficial effects on FEV 1 and FVC with distinct post‐initiation trajectories.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.
- Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Tanawin Nopsopon, Ayobami Akenroye
Förderung
- NIAID NIH HHS
- NIMHD NIH HHS
- NHLBI NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Heart, Lung, and Blood Institute
- National Institute on Minority Health and Health Disparities
Zitieren
APA
Nopsopon, T., Barrett, N. A., Phipatanakul, W., Laidlaw, T. M., Weiss, S. T., & Akenroye, A. (2024). Lung function trajectories in a cohort of patients with moderate‐to‐severe asthma on mepolizumab, omalizumab, or dupilumab. Allergy. https://doi.org/10.1111/all.16002
Vancouver
Nopsopon T, Barrett NA, Phipatanakul W, Laidlaw TM, Weiss ST, Akenroye A. Lung function trajectories in a cohort of patients with moderate‐to‐severe asthma on mepolizumab, omalizumab, or dupilumab. Allergy. 2024. doi:10.1111/all.16002
BibTeX
@article{Nopsopon2024,
author = {Nopsopon, Tanawin and Barrett, Nora A and Phipatanakul, Wanda and Laidlaw, Tanya M and Weiss, Scott T and Akenroye, Ayobami},
title = {Lung function trajectories in a cohort of patients with moderate‐to‐severe asthma on mepolizumab, omalizumab, or dupilumab},
journal = {Allergy},
year = {2024},
doi = {10.1111/all.16002}
}
EUVIMED